Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)

NCT02707328 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

30

Enrollment

OTHER

Sponsor class

Stopped Closed after being on administrative hold

Conditions

Pancreas Cancer
Pancreatic Cancer
Adenocarcinoma of the Pancreas
Pancreas Adenocarcinoma
Pancreatic Adenocarcinoma

Interventions

DRUG: Gemcitabine
DRUG: nab-paclitaxel
RADIATION: CyberKnife

Sponsor

The Cooper Health System